SCHEMBL6316488

SCHEMBL6316488

Nc1onc(-c2ccncc2)c1C(=O)NCc1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
LMNA P02545 1/20 0.53
MAPK14 Q16539 3/20 0.51
HSD17B10 Q99714 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA4 P22748 1/20 0.50
CA7 P43166 1/20 0.50
KMT2A Q03164 2/20 0.48
ATM Q13315 1/20 0.48
ALDH1A1 P00352 5/20 0.46
CYP3A4 P08684 1/20 0.46
THRB P10828 1/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TP53 P04637 1/20 0.45
MEN1 O00255 1/20 0.44
ROCK2 O75116 1/20 0.44
ROCK1 Q13464 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315012 0.88 CA1 (0.50) MAPK14HSD17B10CA1CA2CA4
SCHEMBL6316604 0.88 ALDH1A1 (0.57) L3MBTL1CA1CA2CA4CA7
SCHEMBL6315911 0.81 KMT2A (0.63) L3MBTL1LMNAHSD17B10KMT2AATM
SCHEMBL6315640 0.78 SMN1; SMN2 (0.53) KMT2AALDH1A1SMN1; SMN2ROCK2
SCHEMBL6316553 0.76 ALDH1A1 (0.66) L3MBTL1LMNACA1CA2CA4
SCHEMBL6324120 0.76 ALDH1A1 (0.60) LMNAKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL6315811 0.76 TSHR (0.56) LMNACA1CA2CA4CA7
SCHEMBL6317581 0.76 ALDH1A1 (0.52) KMT2AALDH1A1SMN1; SMN2
SCHEMBL6317470 0.76 ALDH1A1 (0.54) LMNAKMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL6318511 0.74 GAA (0.47) L3MBTL1LMNACA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 L3MBTL1 4176/4885LMNA 3334/4885MAPK14 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.